Veru trims quarterly loss as muscle-preserving obesity trial advances

Veru (NASDAQ:VERU) reported a net loss of $2.7 million, or $0.12 per share, for the three months ended March 31, 2026.

This represents a substantial improvement from the $7.9 million loss ($0.54 per share) reported in the prior-year period.

The results were bolstered by a 21% reduction in general and administrative expenses and a 20% drop in research and development costs as the company streamlines its operations.

The company’s balance sheet also saw a significant boost, with cash and cash equivalents rising to $27.6 million from $15.8 million at the end of the previous fiscal year.

This capital provides a critical bridge as Veru advances its Phase 2b PLATEAU trial, which targets older, obese patients currently taking semaglutide.

The PLATEAU study is designed to address a common side effect of rapid weight loss: the simultaneous loss of muscle and bone density.

By combining enobosarm, an oral selective androgen receptor modulator (SARM), with GLP-1 therapies, Veru aims to trigger "high-quality" weight loss where fat is eliminated but lean body mass is preserved.

Management confirmed that enrollment for the trial is on track, with an interim DXA-based analysis expected in the first quarter of calendar year 2027.

Final topline data from the 68-week study are projected for release in late 2027.